1[1]Packer M.Beta-adrenergic blockade in chronic heart failure:principles,progress,nad prectice.Prog Cardiovasc Dis,1998,48:39～52
2[2]Packer M,Cohn JN,Consensus recommendations for the management of chronic heart failure,Am J Cardiol,1999,83:1～38
3[3]Communal C,Singh K,Pimentel DR,et al.Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway.Circulation,1988,98:1329～1334
4[4]Billman GE,Castillo LC,Hensley J,et al.b2-adrenergic receptor antagonists protect against ventricular fibrillation,In vivo and in vitro evidence for enhanced sensitivity to b2-adrenergic stimulation in animals.susceptible for sudden death,Circulation,1997,96:1914～1992
5[5]Mulieri LA,Hasenfuss G,Leavitt H-P,et al.Altered myocardial force-frequency relation in human heart failure.Circulation,1991,85:1743～1750
7[7]Abraham WT,Tsvetkova T,Lowes BD,et al.Carvedilol improves renal hemodynamics in patients with chronic heart failure [abstract].Circulation,1998,98(suppl Ⅰ):378～379
8[8]Australia-New Zealand Heart Failure Research Collaborative Group.Randomized,placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease,Lancet,1997,349:375～380
9[9]Eichhon EJ,Bristow MR.Medical therapy can improve the biologic properties of the chronically failing heart:a new era in the treatment of heart failure.Circulation,1996,94:2285～2296
10[10]Bropht JN,Joseph L,Rouleau JL.β-blockers in congestive heart failure A Bayesian meta-analysis.Ann Intem Med,2001,134:550～560
